NASDAQ:TSRO

Tesaro Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$74.96
0.00 (0.00 %)
(As of 01/18/2019)
Add
Compare
Today's Range
$74.94
$74.97
50-Day Range N/A
52-Week Range
$23.41
$75.16
Volume1.19 million shs
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38

Competitors

Tesaro (NASDAQ:TSRO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying TSRO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Tesaro, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Tesaro (NASDAQ:TSRO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Amgen291402.48

Amgen has a consensus price target of $255.6190, indicating a potential upside of 1.19%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Tesaro.

Insider & Institutional Ownership

75.2% of Amgen shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Amgen29.42%95.55%15.52%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Amgen$23.36 billion6.21$7.84 billion$14.8217.05

Amgen has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro (NASDAQ:TSRO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Gilead Sciences091302.59

Gilead Sciences has a consensus price target of $99.7391, indicating a potential upside of 47.81%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Tesaro.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Gilead Sciences5.48%37.77%12.76%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Gilead Sciences$22.45 billion3.78$5.39 billion$6.1410.99

Gilead Sciences has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro (NASDAQ:TSRO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Vertex Pharmaceuticals041612.86

Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 37.85%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Tesaro.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Vertex Pharmaceuticals38.51%28.55%20.68%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.63

Vertex Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Tesaro on 12 of the 14 factors compared between the two stocks.

Tesaro (NASDAQ:TSRO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Tesaro and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Regeneron Pharmaceuticals$7.86 billion6.84$2.12 billion$21.4723.40

Regeneron Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Regeneron Pharmaceuticals051402.74

Regeneron Pharmaceuticals has a consensus price target of $656.3810, indicating a potential upside of 30.66%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Tesaro.

Profitability

This table compares Tesaro and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Tesaro on 10 of the 13 factors compared between the two stocks.

Tesaro (NASDAQ:TSRO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Tesaro and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Biogen$14.38 billion2.89$5.89 billion$33.578.21

Biogen has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tesaro and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Biogen4141202.27

Biogen has a consensus price target of $305.5714, indicating a potential upside of 10.87%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Tesaro.

Profitability

This table compares Tesaro and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Biogen35.63%51.00%23.54%

Insider and Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. 33.7% of Tesaro shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Biogen beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro (NASDAQ:TSRO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Tesaro and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tesaro$223.33 million18.48$-496,120,000.00($9.17)-8.17
Alexion Pharmaceuticals$4.99 billion7.61$2.40 billion$9.7417.64

Alexion Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tesaro and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tesaro0000N/A
Alexion Pharmaceuticals015402.21

Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 7.27%. Given Alexion Pharmaceuticals' higher probable upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Tesaro.

Profitability

This table compares Tesaro and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tesaro-295.67%-1,209.72%-83.34%
Alexion Pharmaceuticals16.32%23.16%14.76%

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 33.7% of Tesaro shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Tesaro on 11 of the 13 factors compared between the two stocks.


Tesaro Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$252.62flat$145.14 billion$23.36 billion20.37Analyst Report
Gilead Sciences logo
GILD
Gilead Sciences
2.8$67.48flat$84.96 billion$22.45 billion69.57Analyst Report
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$212.90flat$55.11 billion$4.16 billion26.88Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.34flat$53.82 billion$7.86 billion18.36Earnings Announcement
Analyst Report
Insider Selling
Biogen logo
BIIB
Biogen
1.7$275.61flat$41.49 billion$14.38 billion9.12Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$171.81flat$37.97 billion$4.99 billion40.14Analyst Revision
Seagen logo
SGEN
Seagen
1.7$135.93flat$24.67 billion$916.71 million53.52Insider Selling
Incyte logo
INCY
Incyte
1.6$81.39flat$17.90 billion$2.16 billion-51.84Earnings Announcement
Exact Sciences logo
EXAS
Exact Sciences
2.0$98.84flat$16.96 billion$876.29 million-44.72Earnings Announcement
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$128.63flat$15.12 billion$219.75 million-16.43
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.39flat$13.96 billion$1.70 billion17.48Insider Selling
Novavax logo
NVAX
Novavax
1.6$160.50flat$11.89 billion$18.66 million-30.75Insider Selling
Gap Down
Repligen logo
RGEN
Repligen
1.9$175.13flat$9.62 billion$270.24 million213.57Earnings Announcement
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$91.24flat$8.63 billion$788.10 million98.11Earnings Announcement
United Therapeutics logo
UTHR
United Therapeutics
1.7$189.88flat$8.51 billion$1.45 billion17.96Earnings Announcement
Exelixis logo
EXEL
Exelixis
1.9$24.95flat$7.81 billion$967.78 million51.98Earnings Announcement
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.10flat$6.61 billion$195.99 million288.13Unusual Options Activity
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.24flat$5.11 billion$1.12 billion75.50Earnings Announcement
Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$63.27flat$3.84 billion$806.43 million-8.96Earnings Announcement
Analyst Report
Analyst Revision
Alkermes logo
ALKS
Alkermes
1.2$21.65flat$3.47 billion$1.17 billion-47.05Insider Selling
High Trading Volume
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$59.87flat$3.21 billion$1.11 billion19.25
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.39flat$2.50 billion$182.24 million-8.17News Coverage
Gap Down
OPKO Health logo
OPK
OPKO Health
1.9$3.54flat$2.37 billion$901.90 million-19.64
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$131.87flat$2.17 billionN/A-11.91Earnings Announcement
Analyst Revision
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.93flat$2.12 billion$48.83 million-15.70Earnings Announcement
Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$126.66flat$2.11 billion$120.28 million-127.94Analyst Report
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.11flat$2.01 billion$638.60 million-10.04
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.99flat$1.77 billion$428.41 million15.93Earnings Announcement
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.17flat$1.46 billion$102.43 million-16.95Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.51flat$1.30 billion$82.27 million-15.88Earnings Announcement
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.1$11.77flat$1.19 billion$261.02 million6.01
Codexis logo
CDXS
Codexis
1.5$17.48flat$1.13 billion$68.46 million-49.94Earnings Announcement
News Coverage
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$26.49flat$1.05 billion$3.57 million-11.88Earnings Announcement
Analyst Revision
MannKind logo
MNKD
MannKind
1.4$4.07flat$1.01 billion$63.04 million-19.38Upcoming Earnings
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$17.86flat$992.34 million$227.19 million49.61Earnings Announcement
Analyst Revision
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.90flat$905.05 million$35.22 million-5.77Earnings Announcement
High Trading Volume
News Coverage
Gap Down
Curis logo
CRIS
Curis
1.3$9.73flat$890.48 million$10 million-11.87Upcoming Earnings
Analyst Revision
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$21.94flat$797.04 millionN/A0.00
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.97flat$765.16 million$36.13 million-16.37Analyst Report
Insider Buying
Gap Up
Agenus logo
AGEN
Agenus
1.6$3.01flat$669.55 million$150.05 million-2.76Earnings Announcement
Analyst Revision
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.98flat$641.31 million$150,000.00-4.26Earnings Announcement
Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.39flat$633.71 million$322.07 million-4.18Earnings Announcement
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$16.95flat$562.10 million$252 million-1.73Earnings Announcement
Analyst Report
Analyst Revision
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.29flat$553.15 million$143.01 million-1.01Earnings Announcement
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.17flat$539.42 million$59.29 million-21.13Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.1$2.95flat$506.42 million$17.46 million-2.09High Trading Volume
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07flat$478.04 million$109.33 million-2.26Upcoming Earnings
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.51flat$477.31 million$22.27 million-4.17
Geron logo
GERN
Geron
1.4$1.25flat$398.16 million$460,000.00-3.57
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.78flat$367.62 million$36.63 million-4.45Gap Up
This page was last updated on 5/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.